165 related articles for article (PubMed ID: 38627373)
1. The physiological interactome of TCR-like antibody therapeutics in human tissues.
Marrer-Berger E; Nicastri A; Augustin A; Kramar V; Liao H; Hanisch LJ; Carpy A; Weinzierl T; Durr E; Schaub N; Nudischer R; Ortiz-Franyuti D; Breous-Nystrom E; Stucki J; Hobi N; Raggi G; Cabon L; Lezan E; Umaña P; Woodhouse I; Bujotzek A; Klein C; Ternette N
Nat Commun; 2024 Apr; 15(1):3271. PubMed ID: 38627373
[TBL] [Abstract][Full Text] [Related]
2. Development of a TCR-like antibody and chimeric antigen receptor against NY-ESO-1/HLA-A2 for cancer immunotherapy.
Liu X; Xu Y; Xiong W; Yin B; Huang Y; Chu J; Xing C; Qian C; Du Y; Duan T; Wang HY; Zhang N; Yu JS; An Z; Wang R
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35338087
[TBL] [Abstract][Full Text] [Related]
3. TCR Fingerprinting and Off-Target Peptide Identification.
Karapetyan AR; Chaipan C; Winkelbach K; Wimberger S; Jeong JS; Joshi B; Stein RB; Underwood D; Castle JC; van Dijk M; Seibert V
Front Immunol; 2019; 10():2501. PubMed ID: 31695703
[TBL] [Abstract][Full Text] [Related]
4. Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells.
Cameron BJ; Gerry AB; Dukes J; Harper JV; Kannan V; Bianchi FC; Grand F; Brewer JE; Gupta M; Plesa G; Bossi G; Vuidepot A; Powlesland AS; Legg A; Adams KJ; Bennett AD; Pumphrey NJ; Williams DD; Binder-Scholl G; Kulikovskaya I; Levine BL; Riley JL; Varela-Rohena A; Stadtmauer EA; Rapoport AP; Linette GP; June CH; Hassan NJ; Kalos M; Jakobsen BK
Sci Transl Med; 2013 Aug; 5(197):197ra103. PubMed ID: 23926201
[TBL] [Abstract][Full Text] [Related]
5. Development of a T-cell receptor mimic antibody targeting a novel Wilms tumor 1-derived peptide and analysis of its specificity.
Kurosawa N; Midorikawa A; Ida K; Fudaba YW; Isobe M
Cancer Sci; 2020 Oct; 111(10):3516-3526. PubMed ID: 32770595
[TBL] [Abstract][Full Text] [Related]
6. Development of a CD8 co-receptor independent T-cell receptor specific for tumor-associated antigen MAGE-A4 for next generation T-cell-based immunotherapy.
Davari K; Holland T; Prassmayer L; Longinotti G; Ganley KP; Pechilis LJ; Diaconu I; Nambiar PR; Magee MS; Schendel DJ; Sommermeyer D; Ellinger C
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33771892
[TBL] [Abstract][Full Text] [Related]
7. T cell receptor interactions with human leukocyte antigen govern indirect peptide selectivity for the cancer testis antigen MAGE-A4.
Coles CH; McMurran C; Lloyd A; Hock M; Hibbert L; Raman MCC; Hayes C; Lupardus P; Cole DK; Harper S
J Biol Chem; 2020 Aug; 295(33):11486-11494. PubMed ID: 32532817
[TBL] [Abstract][Full Text] [Related]
8. Elimination of melanoma by sortase A-generated TCR-like antibody-drug conjugates (TL-ADCs) targeting intracellular melanoma antigen MART-1.
Lai J; Wang Y; Wu SS; Ding D; Sun ZY; Zhang Y; Zhou J; Zhou Z; Xu YC; Pan LQ; Chen SQ
Biomaterials; 2018 Sep; 178():158-169. PubMed ID: 29933102
[TBL] [Abstract][Full Text] [Related]
9. Chronic TCR-MHC (self)-interactions limit the functional potential of TCR affinity-increased CD8 T lymphocytes.
Duong MN; Erdes E; Hebeisen M; Rufer N
J Immunother Cancer; 2019 Nov; 7(1):284. PubMed ID: 31690351
[TBL] [Abstract][Full Text] [Related]
10. TCR-mimic bispecific antibodies targeting LMP2A show potent activity against EBV malignancies.
Ahmed M; Lopez-Albaitero A; Pankov D; Santich BH; Liu H; Yan S; Xiang J; Wang P; Hasan AN; Selvakumar A; O'Reilly RJ; Liu C; Cheung NV
JCI Insight; 2018 Feb; 3(4):. PubMed ID: 29467338
[TBL] [Abstract][Full Text] [Related]
11. A major histocompatibility complex-peptide-restricted antibody and t cell receptor molecules recognize their target by distinct binding modes: crystal structure of human leukocyte antigen (HLA)-A1-MAGE-A1 in complex with FAB-HYB3.
Hülsmeyer M; Chames P; Hillig RC; Stanfield RL; Held G; Coulie PG; Alings C; Wille G; Saenger W; Uchanska-Ziegler B; Hoogenboom HR; Ziegler A
J Biol Chem; 2005 Jan; 280(4):2972-80. PubMed ID: 15537658
[TBL] [Abstract][Full Text] [Related]
12. Direct molecular mimicry enables off-target cardiovascular toxicity by an enhanced affinity TCR designed for cancer immunotherapy.
Raman MC; Rizkallah PJ; Simmons R; Donnellan Z; Dukes J; Bossi G; Le Provost GS; Todorov P; Baston E; Hickman E; Mahon T; Hassan N; Vuidepot A; Sami M; Cole DK; Jakobsen BK
Sci Rep; 2016 Jan; 6():18851. PubMed ID: 26758806
[TBL] [Abstract][Full Text] [Related]
13. Specificity of bispecific T cell receptors and antibodies targeting peptide-HLA.
Holland CJ; Crean RM; Pentier JM; de Wet B; Lloyd A; Srikannathasan V; Lissin N; Lloyd KA; Blicher TH; Conroy PJ; Hock M; Pengelly RJ; Spinner TE; Cameron B; Potter EA; Jeyanthan A; Molloy PE; Sami M; Aleksic M; Liddy N; Robinson RA; Harper S; Lepore M; Pudney CR; van der Kamp MW; Rizkallah PJ; Jakobsen BK; Vuidepot A; Cole DK
J Clin Invest; 2020 May; 130(5):2673-2688. PubMed ID: 32310221
[TBL] [Abstract][Full Text] [Related]
14. TCR-like antibody drug conjugates mediate killing of tumor cells with low peptide/HLA targets.
Lowe DB; Bivens CK; Mobley AS; Herrera CE; McCormick AL; Wichner T; Sabnani MK; Wood LM; Weidanz JA
MAbs; 2017; 9(4):603-614. PubMed ID: 28273004
[TBL] [Abstract][Full Text] [Related]
15. Rational development of high-affinity T-cell receptor-like antibodies.
Stewart-Jones G; Wadle A; Hombach A; Shenderov E; Held G; Fischer E; Kleber S; Nuber N; Stenner-Liewen F; Bauer S; McMichael A; Knuth A; Abken H; Hombach AA; Cerundolo V; Jones EY; Renner C
Proc Natl Acad Sci U S A; 2009 Apr; 106(14):5784-8. PubMed ID: 19307587
[TBL] [Abstract][Full Text] [Related]
16. Antigen-specific immunomodulation for type 1 diabetes by novel recombinant antibodies directed against diabetes-associates auto-reactive T cell epitope.
Dahan R; Gebe JA; Preisinger A; James EA; Tendler M; Nepom GT; Reiter Y
J Autoimmun; 2013 Dec; 47():83-93. PubMed ID: 24090977
[TBL] [Abstract][Full Text] [Related]
17. Lysosome-associated membrane glycoprotein 1 predicts fratricide amongst T cell receptor transgenic CD8+ T cells directed against tumor-associated antigens.
Kirschner A; Thiede M; Blaeschke F; Richter GH; Gerke JS; Baldauf MC; Grünewald TG; Busch DH; Burdach S; Thiel U
Oncotarget; 2016 Aug; 7(35):56584-56597. PubMed ID: 27447745
[TBL] [Abstract][Full Text] [Related]
18. Preclinical Studies of the Off-Target Reactivity of AFP
Cai L; Caraballo Galva LD; Peng Y; Luo X; Zhu W; Yao Y; Ji Y; He Y
Front Immunol; 2020; 11():607. PubMed ID: 32395117
[TBL] [Abstract][Full Text] [Related]
19. A TCR targeting the HLA-A*0201-restricted epitope of MAGE-A3 recognizes multiple epitopes of the MAGE-A antigen superfamily in several types of cancer.
Chinnasamy N; Wargo JA; Yu Z; Rao M; Frankel TL; Riley JP; Hong JJ; Parkhurst MR; Feldman SA; Schrump DS; Restifo NP; Robbins PF; Rosenberg SA; Morgan RA
J Immunol; 2011 Jan; 186(2):685-96. PubMed ID: 21149604
[TBL] [Abstract][Full Text] [Related]
20. Antibody specific for the peptide.major histocompatibility complex. Is it T cell receptor-like?
Mareeva T; Lebedeva T; Anikeeva N; Manser T; Sykulev Y
J Biol Chem; 2004 Oct; 279(43):44243-9. PubMed ID: 15302863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
